
Inventor(s): Axel ULLRICH et al. Appl. No.: 09/766,678


FIG. 1

FLK-1 KDR TKR-C	ILIHIGHHLNVVNLLGACTKPGGPLMVIVEFSKFGNLSTYLRGKRNEFVPYKSKGARFRQ
FLK-1 KDR TKR-C	GKDYVGELSVDLKRRLDSITSSQSSASSGFVEEKSLSDVEEEEASEELYKDFLTLEHLIC
FLK-1 KDR TKR-C	YSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARL

Title: USE OF OXGANAC COMA GENERAL FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS








FOR THE INHIBITION OF FLK-1
MEDIATED VASCULOGENESIS AND
ANGIOGENESIS
Inventor(s): Axel ULLRICH et al.
Appl. No.: 09/766,678


FIG. 3A



Tule: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS Inventor(s): Axel ULLRICH et al.


Appl. No.: 09/766,678

FIG. 3B



Title: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS Inventor(s): Axel ULLRICH et al. Appl. No.: 09/766,678

FIG. 3C



Trile: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS Inventor(s): Axel ULLRICH et al.

FIG. 4A






FIG. 4B

Title: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS Inventor(s): Axel ULLRICH et al.


Appl. No.: 09/766,678

FIG. 4E FIG. 4D FIG. 4C

FOR THE INHIBITION OF FLK-1
MEDIATED VASCULOGENESIS AND
ANGIOGENESIS
Inventor(s): Axel ULLRICH et al.

Appl. No.: 09/766,678

FIG. 5A







FIG. 5B

FOR THE INHIBITION OF FLK-1
MEDIATED VASCULOGENESIS AND
ANGIOGENESIS

Inventor(s): Axel ULLRICH et al. Appl. No.: 09/766,678

FIG. 5C






FIG. 5D

FIG. 6A







FIG. 6B

Title: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS Inventor(s): Axel ULLRICH et al.

Appl. No.: 09/766,678

FIG. 7A







FIG. 7B

FOR THE INHIBITION OF FLK-1
MEDIATED VASCULOGENESIS AND
ANGIOGENESIS
Inventor(s): Avel III I RICH et al

FIG. 7C






FIG. 7D





FIG. 8B



F1G. 8A

Inventor(s): Axel ULLRICH et al.

Appl. No.: 09/766,678









FIG. 8C










FIG. 13

Inventor(s): Axel ULLRICH et al. Appl. No.: 09/766,678

FIG. 11-1

75 150	iGG IGG	CAG CC <i>P</i>	AGC GGG	TGG TGC	GGC CTT	CGC CTT	AGC TGA	AC TG	CTO CTO	CCG CGC	ACA TAC	icge icc <i>e</i>	TCC(GGG(GAT GCG	CCC GCT	TGA TGC	GGC	CCT	AAT.	GGA TCT	CCG CGC	CAG	CCG	GTC	CTGT
225	CGC	GGC A	CAA	GAG S	GGA	GAT	CAG	iTG	AGO	GCG	GGC	CCA	GTG	TCT	GGC	CTG	AAA	GAG	CCT	GTG	TCT	GAG	AAG	GAG	GAC(
300	ATC P	CC <i>P</i> H	TCT L	TTT F	CGA D	TGG G	GAC T	TT L	GGT G	GTG V	TCT S	GCC A	AGC(CCG R	GAC T	GGA E	CGT V	CTG C	GTT F	GTG W	TCT L	CGC A	TGT V	AGC A	rgc: L
375	SAC Q	GGG G	iCAG R	TTG C	TAC T	GAT I	TCA Q	CCT L	AC(T	ACA T	AAT N	GC <i>F</i> A	TTT(AAT I	GAC T	ACT L	CAT I	AGA D	GAA K	ACA Q	CAC T	CAG S	GCT L	CAA K	CCC(
450	G G	CG0 G	ATG C	TGA E	GAC T	GGT V	ATT L	GGT V	AG(R	GAA E	GAG E	TC1 S	TGA D	GCG R	TCA Q	TGC A	CAA N	iGCC P	TTG W				CCT L		AGC(R
525	S S	GT0 C	CAA K	CTA Y	AGC A	TGG G	TAC T	rga D	AA] N	GGA G	GTT V	GT(V	CAG R	TCC P	CAT I	CAC T	ACT L	AAC T	CAA K		CTT F			TGA D	GTG(
600	CTG V	CT(S	CGC A	CAT I	ATT F	ACC P	ATC S		TA(Y		CGA R	rgti V	CTA Y	TGT V	TTA Y	TGT V	CAC T	CTC S	AGC A	CAT I	CGA D	CGT V		CCG R	
675	CGA I	GT(S	GAGG	CCG R	CTE C	CCC P	GAT I	GGT V	GT(V			AA(N	CAA K	GAA N	CGA E			GT <i>P</i>				AGCA H		TGA D	TCA(
750	CCT W	TT(TAAE I	CAG R	AAA N	TGG G	GGA D	rcc P		TTT F	AGA R	AAA(K	AGA E		GTA Y			_	CTCT L		TGT V			AAA: N	TTT S
825	AGA I	AA/ K	AGGC A	TG <i>A</i> E	CTG C	CTT F	GGT V	CAT M	GG(G	GCC A	TAT Y	CAG(S	GAT I						TAC T					ACA6 S	
900	ГGA S	TCT L	GAT I	TG1 V	TG/ D	TTA Y	GAT I	ΓΑG R	TA [*] Y	GGA G	GT <i>A</i> V	GGT V	TGT V											ATG <i>A</i> D	
975	ATG V	CA/ N	AGCT L	AG <i>I</i> E	AA(T	GAG R	AGC A	TAC T	TG C	AAT N	TT#	TGT(ACT L	AAA K	GAG <i>F</i> E	CCGG	CTG(A	rat(S	AGC1 L	TG/ E	I AA	ATG <i>I</i> E	CGC <i>I</i> H	CCC(P	GCC P
1050	AAC P	GA/	ATGT V	GG/ D	CC(R	AAA N	TGT V	GAT I	AA(K	AA0 K	CAT H	TCA H	GTC S	AAA K	CTT(S	CACC P	CTC(P	ACT(S	GGC <i>I</i> H	CT(CAC T	ATTI F	rtg <i>i</i> D	GGCT L	TGG G
1125	GGG E	AG(G	ACCA Q	TG/ D	GA(S	CAA K	GAC T	TG1 V	AG S	GAA E	AT <i>I</i>	GAC. T	CTT L	CAC T	rga(S	rtti L	rgti F	AGA? M	CGA/ K	rgg(A	CTGT V	GGA(T	CTG(G	TTC(P	CCT F
1200	CTT F	IGC(CAAA K	CA(TC/ H	AGT V	CCG R	TG1 V	TT F	AC <i>I</i> T	AG <i>A</i>	AAA N	GAG R	CA/	ΓGΑ Ι	GGAT M	GAC(R	GTG(CCA(S	GT(S	FAG(A	GTGT V	CCT(ACA(T	AAT Y
1275	AGT Y	GA K	CTGT V	CC(AAi I	CCG R	AGT V	TC# Q	AG S	GG(G	GT(V	CAC. T	AGC A	rgg/ E	rgg V	CTTI L	AAT(S	ГGA/ К	GGA ⁻ M	GTG(STAG S	гсg(G	CTT F	TTG(A	TTA I
1350	TTG	GA	CAAT	(CA	CT/	CAA	GTC	TG <i>I</i>	CAT	icc(AG(TGG.		ACA(GGT/)TA	TCA/	ATA [°]	CTG/	CTC	CAGO	ACC(GTT	TCA(ATC

Title: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND **ANGIOGENESIS** Inventor(s): Axel ULLRICH et al.

Appl. No.: 09/766,678

FIG. 11-2

TTGGCGATGAACTCACCATCATGGAAGTGACTGAAAGAGATGCAGGAAACTACACGGTCATCCTCACCAACCCCA 1425 G D E L T I M E V T E R D A G N Y T V I L T N P I TTTCAATGGAGAAACAGAGCCACATGGTCTCTCTGGTTGTGAATGTCCCACCCCAGATCGGTGAGAAAGCCTTGA 1500 S M E K Q S H M V S L V V N V P P Q I G E K A L I TCTCGCCTATGGATTCCTACCAGTATGGGACCATGCAGACATTGACATGCACAGTCTACGCCAACCCTCCCCTGC 1575 S P M D S Y Q Y G T M Q T L T C T V Y A N P P L H ACCACATCCAGTGGTACTGGCAGCTAGAAGAAGCCTGCTCCTACAGACCCGGCCAAACAAGCCCGTATGCTTGTA 1650 H I Q W Y W Q L E E A C S Y R P G Q T S P Y A C K AAGAATGGAGACACGTGGAGGATTTCCAGGGGGGAAACAAGATCGAAGTCACCAAAAACCAATATGCCCTGATTG 1725 EWRHVEDFOGGNKIEVTKNOYALIE AAGGAAAAACAAAACTGTAAGTACGCTGGTCATCCAAGCTGCCAACGTGTCAGCGTTGTACAAATGTGAAGCCA 1800 G K N K T V S T L V I Q A A N V S A L Y K C E A I TCAACAAAGCGGGACGAGGAGAGAGGGTCATCTCCTTCCATGTGATCAGGGGTCCTGAAATTACTGTGCAACCTG 1875 N K A G R G E R V I S F H V I R G P E I T V Q P A A Q P T E Q E S V S L L C T A D R N T F E N L T W Y K L G S Q A T S V H M G E S L T P V C K N L D A CTCTTTGGAAACTGAATGCACCATGTTTTCTAACAGCACAAATGACATCTTGATTGTGGCATTTCAGAATGCCT 2100 L W K L N G T M F S N S T N D I L I V A F Q N A S CTCTGCAGGACCAAGGCGACTATGTTTGCTCTGCTCAAGATAAGAAGACCAAGAAAAGACATTGCCTGGTCAAAC 2175 L Q D Q G D Y V C S A Q D K K T K K R H C L V K Q AGCTCATCATCCTAGAGCGCATGGCACCCATGATCACCGGAAATCTGGAGAATCAGACAACCATTGGCGAGA 2250 LIILERMAPMITGNLENQTTTIGET CCATTGAAGTGACTTGCCCAGCATCTGGAAATCCTACCCCACACATTACATGGTTCAAAGACAACGAGACCCTGG 2325 I E V T C P A S G N P T P H I T W F K D N E T Ł V E D S G I V L R D G N R N L T I R R V R K E D G G GCCTCTACACCTGCCAGGCCTGCAATGTCCTTGGCTGTGCAAGAGCGGAGACGCTCTTCATAATAGAAGGTGCCC 2575 LYTCQACNVLGCARAETLFIIEGAQ AGGAAAAGACCAACTTGGAAGTCATTATCCTCGTCGGCACTGCAGTGATTGCCATGTTCTTCTGGCTCCTTCTTG 2550 EKTNLEVIIL V G T A V I A M F F W L L L V TCATTGTCCTACGGACCGTTAAGCGGGCCAATGAAGGGGAACTGAAGACAGGCTACTTGTCTATTGTCATGGATC 2625 I V L R T V K R A N E G E L K T G Y L S I V M D P

Title: USE OF ORGANIC COMPOUNDS FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS Inventor(s): Axel ULLRICH et al.

Inventor(s): Axel ULLRICH et Appl. No.: 09/766,678

FIG. 11-3

2700	ACC R	GGA D	CAG R	CCC P	ATT F	GGA E	GTG W	CAA K	CAG S	TGC A	TGA D	TTA Y	GCC P	CTT L	ACG R	TGA E	CTG C	GCG R	TGA E	GGA D	CTT L	GC(P	ATT L	TGA E	CAG <i>A</i> D
2775	ACA K	TGA D	AAT I	TGG G	TTT F	CGC A	AGA D	GGC A	rga(E	GAT I	AGT V	CCA Q	CGG G	CTT F	TGC A	CGG G	CCG R	TGG G	TCT L	ACC P	AAA K	AG(ACT L	GAA K	GGCT L
2850	ΓCA M	CC1 L	AGC A	TCG R	GCA H	CGA E	CAG S	ACA H	AAC. T	AGC. A	AGG G	AGA E	GAA K	GTT L	GAT M	CAA K	CGT V	AGC A	AGT V	AAC T	GCAA K	TT0 C	GAC T	AGC A	AGAC T
2925	AGC P	CAA K	CAC T	CTG C	CGC A	AGG G	CCT L	CCT L	GAA N	GGT V	TGT V	CAA N	TCT L	CCA H	TCA H	TGG G	CAT I	CCA H	CAT I	CCT L	AGAT I	CA/ K	ACT L	TGA E	TGT(S
3000	AA6 N	GAG R	CAA K	GGG G	ACG R	CTT L	TTA Y	AAC T	ATC. S	CCT. L	AAA N	TGG G	GTT F	GAA K	CTC S	ATT F	GCA Q	TCT L	GAT I	GGT V	CAT M	TC1 L	GCC P	AGG G	CGG(
3075	TGG D	CGT V	CTC S	GCT L	GGA E	TGG G	CGT V	CTA Y	GGA D	CAA K	GGG G	CCA Q	CCG R	CTT F	ACG R	GGC A	AGG G	CAA K	GAG S	TAA K	CCT <i>P</i> Y	TC(P	TGT V	ATT F	ATG/ E
3150	CGC L	ATC S	GAA K	GGA E	TGA E	TGT V	CTT F	AGG G	CTC. S	CAG S	TGC A	CTC S	GAG S	CCA Q	CAG S	CAG S	CAC T	CAT I	CAG S	rgg <i>e</i> D	GCTT L	AC(R	AAG R	GAA K	ATC1
3225	TT6 Y	CTO C	CAT I	TCT L	GCA H	GGA E	CTT L	GAC T	CCT L	CTT F	GGA D	CAA K	GTA Y	ACT L	AGA E	TGA E	STTC	AGC A	AGA E	AG <i>A</i> E	AGG <i>F</i> E	AG/ E	TGT V	TGA D	TCA6 S
3300	GAA N	ACG R	AGC A	GGC A	CCT L	GGA D	CAG R	CCA H	TAT: I	GTG C	GAA K	AAG R	ATC S	GGC A	CTT L	GTT F	GGA E	GCAT M	GGG	CTA# K	rgg(A	AG ⁻ V	CC <i>I</i> Q	CTT F	ACA(S
3375	CGG D	P P	AGA D	TAA K	TTA Y	CAT I	GGA D	CCG R	GGC A	CTT L	CGG G	CTT F	TGA D	CTG C	GAT I	TAA K	rggt V	ATGT V	AGA <i>P</i> N	AGAA K	CGG/ E	rato S	CC1 L	TCT L	ACA ^T
3450	₹CA T	AT <i>A</i> Y	AGT V	CAG R	TGA D	TTT F	CAT I	AAC T	GGA. E	CCC P	GGC A	GAT M	GTG W	GAA K	TTT L	CCC P	SACT L	CCC R	ATG(A	AGA D	AAG0 G	AA K	CA(TGT V	ATT/ Y
3525	CTG G	CC(ATA Y	CCC P	CTC S	TGC A	AGG G	CTT L	TTC S	ATT F	AAT I	GGA E	CTG W	GCT L	GTT L	TGT V	rcge G	CTT1 F	GT(S	rgto W	ATGT V	GCG/ D	GA(S	TCA Q	CAA ⁻
3600	CC P	TAC T	CAC T	CTA Y	TGA D	TCC P	GGC A	GCG R	AAT M	TAG R	AAC T	AGG G	AGA E	GAA K	ATT L	iGAG R	TAG R	C C	AT1 F	AAG/ E	ATG/ E	rTG/ D	GAT	CAA K	GGG ⁻ V
3675	rgg E	GGT V	GTT L	AGA E	TTC S	GTT F	CTC S	ACC P	GAG R	CCA Q	CAA N	CCC P	IGGA D	TG <i>P</i> E	iGC <i>P</i> H	CTG W	ACTO C	rgg <i>i</i> D	rgct L	CCAT M	AGA(T	ACC. Q	GT/ Y	TAAI M	CAG/ E
3750	4GA T	AG <i>I</i> E	GTC S	AAT M	TCC P	TCT L	TGT V	TAT I	CTA Y	AGA D	CAA K	TG0 G	IGGA D	GC <i>A</i> Q	GC <i>A</i> Q	ATGC A	CAAA N	AAG(A	rgc <i>i</i> Q	rcc L	ACC ⁻ L	AAE N	GG(ATTT L	AGC/ H
3825	ГGТ С	AGT V	IGGA E	AGA E	GGA E	GGA E	TAT M	CTG C	TTC S	TGT V	ACC P	CTC S	TAC T	GC(P	CCT L	CTC S	GACT L	CTG(G	ATT(S	AGG/ D	AAG/ E	rgg. E	iCAT M	rgae S	CAC [*]
3900	GGC P	CCC R	GAG S	AAA K	GCG R	TAA K	CAG S	GAA N	CCA Q	TCT L	TTA Y	TC <i>P</i> H	CAG	I I	AGG G	AGC A	ACA(T	ACA/ N	ATG/ D	ATT/ Y	ТСС <i>I</i> Н	AAT F	CA/ K	ACCO P	GCG/

Tule: USE OF ORGANIC COMPOUNDS
FOR THE INHIBITION OF FLK-1
MEDIATED VASCULOGENESIS AND
ANGIOGENESIS
Inventor(s): Axel ULLRICH et al.

Inventor(s): Axel ULLRICH et al Appl. No.: 09/766,678

FIG. 11-4

CAGT V	GAG S	TGT V	AAA K	AAC T	ATT F	TGA. E	AGA D	TAT I	CCC P	ATT L	GGA E	GGA E	ACC P	AGA E	AGT V	AAA K	ÀGT V	GAT I	CCC. P	AGA D	TGA D	CAG S	CCA Q	GA T	3975
CAGA D	CAG S	TGG G	GAT M	GGT V	CCT L	TGC.	ATC. S	AGA E	AGA E	GCT L	GAA K	AAC T	TCT L	GGA E	AGA D	CAG R	igaa N	CAA K	ATT. L	ATC S	TCC P	ATC S	TTT F	TG G	4050
GTGG G	AAT M	GAT M	GCC P	CAG S	TAA. K	AAG(S	CAG R	GGA E	GTC S	TGT(GGC A	CTC S	GGA E	AGG G	CTC S	CAA N	CCA Q	GAC T	CAG S	TGG G	CTA Y	CCA Q	GTC S	TG G	4125
GGTA Y	TCA H		AGA	TGA D	CAC	AGA(CAC	CAC	CGT	GTA	CTC	CAG	CGA D	CGA F	GGC A	AGG G	ACT	TTT.	AAA K	GAT M	GGT V	GGA	TGC A	TG A	4200
•	••	S	_	_	l .	_	•	•	•	•	•			_	•	_	_	_			•				4075
CAGT V	TCA H	CGC A	TGA D	CTC S	AGG G	GAC(CAC. T	ACT L	GAG S	CTC/ S	ACC P	I CC P	V	HA	AAI	GGA	AG I	GGT	CCI	alt	LLU	ibl I	LLG	LL	4275
CCCA	۸СТ	ጉጉፕ	CCA	ΛΛΤ	ር ል ር ነ	CAG	۸۵۸	сст	сст	CCT.	TAG	A T T	TTC	ልልቤ	TGT	тст	тст	TTC	<u>ጉል</u> ጉ	_{ርል} ሮ	ՐՐԲ	GAA	GTA	GC	4350
CACA																									4425
TGCC																									4500
GTGG																									4575
TCTG																									4650
																								٠.	4725
ACCT																									4800
GCGC																								٠.	4875
GTCA																									4950
GAGT																									
GAAG																									5025
GTCG																									5100
CCCA																									5175
TCTA																									5250
AATT																							AAC	. ,	5325
CTAC	TGT.	ATC	CTT	TAG	AAT'	TTT/	AAC	CTA	TAA.	aac'	IAT	aTC'	IAC	TGG	H	UIG	CCT	GIG	IGC	ΙIΑ	161	1			5393




FIG. 12A




FIG. 12B

FOR THE INHIBITION OF FLK-1 MEDIATED VASCULOGENESIS AND ANGIOGENESIS

